NSPR

Business Context and Reporting Period

Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: InspireMD is a medical device company developing the MicroNet stent platform for vascular and coronary disease. Its primary commercial product is the CGuard EPS carotid stent system, marketed internationally. The company is currently seeking FDA approval for its CGuard Prime system in the U.S. following positive results from the C-GUARDIANS pivotal trial.

Key Financial Metrics

Note: All financial figures are in U.S. dollars in thousands, except per share data.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 16.3% in Q3 2024 and 13.9% for the nine months ended September 30, 2024, driven by growth in existing and new international markets (Europe, Asia, Middle East).
• Margin Compression: Gross margin declined to 22.9% in Q3 2024 (from 28.1% in Q3 2023) and 20.5% for the nine-month period (from 29.3% in 2023). This was due to increased material/labor costs, facility maintenance downtime, and higher compensation expenses.
• Operating Expenses: Total operating expenses rose significantly.
  • R&D: Increased 85.5% in Q3 and 67.2% for the nine months, primarily due to SwitchGuard NPS development, regulatory costs for the CGUARDIANS II study, and hiring for U.S. expansion.
  • Selling & Marketing: Increased 68.0% in Q3 and 62.5% for the nine months, driven by building U.S. commercial infrastructure.
  • G&A: Increased 12.9% in Q3 and 36.2% for the nine months, largely due to share-based compensation.
• Capital Raise: In Q3 2024, the company received net proceeds of approximately $16.9 million from the full exercise of Series H warrants following the announcement of positive one-year clinical trial results.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $244.3 million and expects to continue incurring losses until commercial profitability is reached. Current resources are deemed insufficient to fund operations for the next 12 months without additional financing.
• Regulatory Milestones:
  • Submitted a Premarket Approval (PMA) application to the FDA in September 2024 for the CGuard Prime carotid stent system.
  • Received FDA approval in October 2024 for the IDE to initiate the CGUARDIANS II pivotal study for the CGuard Prime 80cm system in TCAR procedures.
• Geopolitical Risk: The company's sole manufacturing facility and executive offices are in Israel. While operations have not been materially disrupted to date, the ongoing war and regional instability pose significant risks to supply chains, personnel availability (military conscription), and overall business continuity.
• Liquidity Strategy: The company plans to raise capital through equity sales, debt, strategic partnerships, or warrant exercises. An At-The-Market (ATM) facility with Piper Sandler was established in May 2024, with limited sales to date.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of current cash ($15.8M) and marketable securities ($24.6M) against the stated need for additional financing within 12 months.
• FDA Timeline: Monitor the status of the PMA application submitted in September 2024 and the timeline for potential FDA approval of CGuard Prime.
• Israel Operations: Assess the impact of the ongoing conflict in Israel on the company's sole manufacturing facility and employee availability.
• Dilution Risk: Review the outstanding warrant positions (approx. 40.3 million shares) and pre-funded warrants (approx. 26.1 million shares) and their potential impact on share count upon exercise.
• Revenue Concentration: Note that no single customer accounts for more than 17% of revenue, but the company relies heavily on international distributors, primarily in Europe.